Filing Flows › Rani Therapeutics Holdings (RANI) › Q3 2026 › vs Q2 2026
Rani Therapeutics Holdings (RANI) Q3 2026 vs Q2 2026 (quarter over quarter)
Rani Therapeutics Holdings's revenue fell $1K (-0.1%) from $1.7M in Q2 2026 to $1.7M in Q3 2026.
Rani Therapeutics Holdings, Q3 2026: revenue $1.7M, operating margin -540.3%, net loss $8.8M, operating cash flow −$7.8M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.7M | $1.7M | −$1K | -0.1% |
| Other income, net | $417K | $407K | $10K | +2% |
| Net loss | $8.8M | $8.4M | $385K | +5% |
| Costs & expenses | $10.9M | $10.5M | $394K | +4% |
| Operating costs | $10.9M | $10.5M | $394K | +4% |
| Research & development | $6.0M | $5.0M | $1.0M | +20% |
| General & admin | $4.9M | $5.5M | −$610K | -11% |
| Operating cash sources | $10.1M | $11.6M | −$1.5M | -13% |
| Depreciation & amortization | $123K | $152K | −$29K | -19% |
| Share-based compensation | $2.2M | $2.4M | −$209K | -9% |
| Cash used in operations | $7.8M | $9.0M | −$1.3M | -14% |
| Net loss absorbed | $8.8M | $8.4M | $385K | +5% |
| Working capital & other | $1.3M | $3.2M | −$1.9M | -59% |
Questions
How much did Rani Therapeutics Holdings's revenue grow quarter over quarter in Q3 2026?
Rani Therapeutics Holdings's revenue fell $1K (-0.1%) from $1.7M in Q2 2026 to $1.7M in Q3 2026.